Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients

[1]  D. Cunningham,et al.  Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicenter, randomized phase III trial (the UK ABC-02 trial). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Chua,et al.  Clinicopathologic and Treatment-Related Factors Influencing Recurrence and Survival after Hepatic Resection of Intrahepatic Cholangiocarcinoma: A 19-Year Experience from an Established Australian Hepatobiliary Unit , 2010, Journal of Gastrointestinal Surgery.

[3]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[4]  Myung-Hwan Kim,et al.  Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study , 2009, Gut and liver.

[5]  M. Highley,et al.  Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study , 2009, British Journal of Cancer.

[6]  J. Chung,et al.  The Prognosis and Survival Outcome of Intrahepatic Cholangiocarcinoma Following Surgical Resection: Association of Lymph Node Metastasis and Lymph Node Dissection with Survival , 2009, Annals of Surgical Oncology.

[7]  T. Greten,et al.  A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Trarbach,et al.  Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. , 2009, Journal of the American College of Surgeons.

[9]  A. Zhu,et al.  Systemic therapy for biliary tract cancers. , 2008, The oncologist.

[10]  Maria Hawkins,et al.  Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Schneider,et al.  Transarterial Chemoembolization (TACE) for Inoperable Intrahepatic Cholangiocarcinoma , 2007, CardioVascular and Interventional Radiology.

[12]  G. Gores,et al.  Cholangiocarcinoma: modern advances in understanding a deadly old disease. , 2006, Journal of hepatology.

[13]  W. Guo,et al.  Consideration of the Role of Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Analysis of 75 Patients , 2006, Cancer journal.

[14]  Peter C Levendag,et al.  Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study , 2006, Acta oncologica.

[15]  L. Qin,et al.  Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. , 2005, International journal of radiation oncology, biology, physics.

[16]  Xiao-dong Zhu,et al.  [Prognostic factor of primary liver cancer treated by hypofractionated three-dimensional conformal radiotherapy]. , 2005, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[17]  M. Makuuchi,et al.  Report of the 15th follow-up survey of primary liver cancer. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[18]  W. Guo,et al.  A Comparison of Chemoembolization Combination With and Without Radiotherapy for Unresectable Hepatocellular Carcinoma , 2004, Cancer journal.

[19]  Guang-shun Yang,et al.  Clinicopathologic features, diagnosis and surgical treatment of intrahepatic cholangiocarcinoma in 104 patients. , 2004, Hepatobiliary & pancreatic diseases international : HBPD INT.

[20]  K. McGlynn,et al.  Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? , 2004, Journal of hepatology.

[21]  Myung Ah Lee,et al.  Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[22]  S. Curley,et al.  Limitations of conventional doses of chemoradiation for unresectable biliary cancer. , 2002, International journal of radiation oncology, biology, physics.

[23]  K. Hanazaki,et al.  Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. , 2002, Hepato-gastroenterology.

[24]  W. Jarnagin,et al.  Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. , 2001, Journal of the American College of Surgeons.

[25]  M. Bloomston,et al.  Location, not Staging, of Cholangiocarcinoma Determines the Role for Adjuvant Chemoradiation Therapy , 2001, The American surgeon.

[26]  W. Curran,et al.  Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. , 2000, International journal of radiation oncology, biology, physics.

[27]  T. Linné,et al.  Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Y. Kawarada,et al.  Diagnosis and treatment of cholangiocellular carcinoma of the liver. , 1990, Hepato-gastroenterology.